LivaNova (NASDAQ:LIVN) Stock Rating Upgraded by Wolfe Research

LivaNova (NASDAQ:LIVN - Get Free Report) was upgraded by investment analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating in a note issued to investors on Tuesday,Finviz reports. The brokerage presently has a $60.00 price target on the stock. Wolfe Research's target price suggests a potential upside of 36.46% from the stock's previous close.

Several other equities research analysts have also recently commented on LIVN. Mizuho lowered their target price on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus dropped their price objective on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. The Goldman Sachs Group cut their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. StockNews.com cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, Robert W. Baird boosted their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $59.29.

LivaNova Price Performance

LIVN opened at $43.97 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The stock has a market capitalization of $2.40 billion, a P/E ratio of 104.69 and a beta of 0.84. The company's 50 day simple moving average is $38.49 and its 200-day simple moving average is $44.76. LivaNova has a one year low of $32.48 and a one year high of $62.04.

Institutional Investors Weigh In On LivaNova

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of LivaNova by 13.5% during the first quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company's stock worth $104,755,000 after purchasing an additional 316,993 shares in the last quarter. Capital Research Global Investors raised its stake in LivaNova by 19.1% during the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock worth $74,690,000 after buying an additional 258,730 shares during the period. AQR Capital Management LLC lifted its holdings in LivaNova by 111.7% during the first quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company's stock worth $60,809,000 after acquiring an additional 829,115 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in LivaNova by 8.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company's stock worth $60,710,000 after acquiring an additional 107,693 shares in the last quarter. Finally, Redmile Group LLC grew its stake in LivaNova by 19.3% in the fourth quarter. Redmile Group LLC now owns 1,043,539 shares of the company's stock valued at $48,326,000 after acquiring an additional 168,500 shares during the period. Institutional investors own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.